Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Lomb Ord Shs T.BLCO

Alternate Symbol(s):  BLCO

Healthcare Medical Devices
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative... see more

Recent & Breaking News (TSX:BLCO)

Bausch + Lomb Announces U.S. Launch of StableVisc(TM) Cohesive Ophthalmic Viscosurgical Device and TotalVisc(TM) Viscoelastic System

Business Wire April 24, 2023

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Business Wire April 20, 2023

Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Business Wire April 18, 2023

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

Business Wire April 17, 2023

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma(TM) Fully Digital Surgical Visualization Platform

Business Wire April 13, 2023

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

Business Wire April 12, 2023

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

Business Wire March 22, 2023

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

Business Wire February 22, 2023

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Business Wire February 15, 2023

New Bausch + Lomb Social Media Campaign Highlights What 'Sights' Inspire AMD Patients

Business Wire February 7, 2023

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE® (Verteporfin for Injection)

Business Wire February 1, 2023

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

Business Wire January 23, 2023

Bausch + Lomb Acquires AcuFocus, Inc.

Business Wire January 17, 2023

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb(TM)

Business Wire January 9, 2023

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 9, 2023

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2023

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Business Wire January 4, 2023

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

Business Wire January 3, 2023

Bausch + Lomb Amends CEO Separation Agreement

PR Newswire December 22, 2022

Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

PR Newswire December 13, 2022